OneSource Specialty Pharma Limited has submitted a regulatory clarification in response to an earlier intimation by Dr. Reddy's Laboratories (DRL) regarding delays in commercial supplies of Semaglutide for a certain period of time. The company references its earlier communications about its tie-up with DRL as a Manufacturing Partner for Generic Semaglutide Injection.
Key Clarifications
- The delay in commercial supplies as disclosed by DRL does not have any material impact, financially or otherwise, on OneSource's operations
- OneSource maintains its commitment to its long-standing partnership with DRL
- The company has sufficient demand for the product from other customers, including for the Canadian market
- Current manufacturing capacities are fully committed
Capacity Expansion Plans
- Significant new capacities are being added starting current quarter (Q2 2026)
- Additional capacity additions planned later in the year (2026)
- Expansion is in line with previously communicated plans
- The company will be positioned to supply all of DRL's demand as soon as they are ready
Business Focus
The company remains focused on executing its growth plans and serving global customers with high standards of quality, reliability, and supply continuity.